Loading…
Chinese maker of mass spectrometry instruments for environmental monitoring, biomedicine, food safety and industry.
Chinese maker of mass spectrometry instruments for environmental monitoring, biomedicine, food safety and industry.
Sells instruments mainly to government monitoring bodies and labs, often through public tenders, so orders follow government environmental and food-safety budgets. After-sales service and software add repeat revenue, while foreign makers still hold most of the high-end market.
In one line: A Chinese Thermo Fisher/Agilent for mass spectrometers.
Moat: narrow (IP / patents, process know-how). Domestic mass-spec instrument know-how, though global majors dominate high-end segments.
Headquarters: Guangzhou, Guangdong, China · Founded: 2004 · Employees: 199
Size Guangzhou Hexin Instrument (688622.SS) is a China Health Care company (Medical Specialties) with a market value of $1.26B, the 1900th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥118.78 on 6 Nov 2026.
Performance Over six months the shares gained 58.4%, against -8.1% for the median peer and -16.4% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue fell 28.7% over the last twelve months (peer median +14.5%); the operating margin is -73.5% (peer median 16.0%).
Valuation It trades at 99.9× enterprise value to sales against a peer median of 4.3× (most expensive of 20).
Capital Return on invested capital runs 15.2 points below its cost of capital (8.5% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥86.2M | CN¥99.1M | CN¥200M | CN¥364M | CN¥278M |
| Revenue growth | — | -50% | -45% | +31% | — |
| Gross profit | CN¥46.2M | CN¥17.3M | CN¥50.8M | CN¥116M | CN¥115M |
| EBITDA | n/a | -CN¥42.8M | -CN¥41.9M | -CN¥103M | -CN¥91.4M |
| Net income | -CN¥87.9M | -CN¥94.8M | -CN¥46.0M | -CN¥96.1M | -CN¥63.3M |
| Free cash flow | -CN¥24.1M | -CN¥24.6M | -CN¥78.1M | -CN¥145M | -CN¥161M |
| Capital expenditure | CN¥30.9M | CN¥33.8M | CN¥69.9M | CN¥109M | CN¥77.6M |
| Total debt | CN¥311M | CN¥281M | CN¥285M | CN¥356M | CN¥249M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Guangzhou Hexin Instrument 688622.SS | $1.26B | +58% | -29% | -74% | 99.9× | n/a |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 6.2× | 20.9% |
| Agilent Technologies A | $49.3B | +51% | +9% | 24% | 7.0× | 22.6% |
| JEOL 6951.T | $1.98B | -3% | -18% | 11% | 1.8× | 21.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688622.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.0% | +0.9% | 9th highest of 21 |
| 6-month return | +58.4% | -8.1% | 2nd highest of 21 |
| Distance from 52-week high | -28.5% | -35.8% | 8th highest of 21 |
| Revenue growth (TTM) | -28.7% | +14.5% | lowest of 20 |
| Operating margin | -73.5% | 16.0% | lowest of 20 |
| EV / Sales | 99.9× | 4.3× | most expensive of 20 |
| ROIC minus cost of capital | -15.2 pp | +0.9 pp | 4th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | 99.9× | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 4.6× | -8.7% | +34.5% |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 3.3× | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 5.2× | 10.8% | +40.3% |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 5.1× | 12.7% | -3.5% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 11.7× | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | 3.0× | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | 1.4× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | 12.7× | 53.9% | +8.6% |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 4.3× | n/a | n/a |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 2.0× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 6.8× | 10.0% | +8.8% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 5.8× | 1.5% | +9.9% |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 3.6× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 2.2× | 2.2% | +19.7% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | 3.4× | n/a | n/a |
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 28% | 4.2× | 9.9% | +16.5% |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 11.7× | 19.1% | +21.5% |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 5.2× | 6.5% | +10.3% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 2.0× | 9.8% | +7.7% |